In the long human struggle against cancer, one of medicine's most ingenious tools—engineering a patient's own immune cells to seek and destroy tumors—has been undermined by a quiet act of self-defeat. Researchers at the University of Maryland have now identified the molecular mechanism behind this failure: a protein called cathepsin b that causes CAR T-cells to absorb fragments of the very cancer cells they attack, dulling their own effectiveness. By blocking this protein, scientists restored the cells' durability and fighting power in preclinical models, opening a path toward clinical trials
Newswise
· Jun 13, 2026
· health
· 2 min de leitura
High
Apuração: Verificado
Researchers Identify Protein Target to Boost CAR T-Cell Therapy Effectiveness
Relevant to blood cancer patients experiencing relapse within 5 years of CAR T-cell therapy treatment.
◉
Health & Medicine
8252 artigos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% correspondência
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% correspondência
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% correspondência
Cobertura Relacionada
World Socialist Web Site · Aug 22
H5N1 avian flu spreads across Australia with 290 confirmed infections
Australia faces a rapidly spreading H5N1 avian flu outbreak with 290 confirmed infections across all states, threatening…
Devdiscourse · Aug 22 Congo's Bundibugyo Crisis: Health Attacks Threaten Economic Stability Beyond Medical ResponseWHO warns that violence and attacks on health facilities in eastern DRC's Bundibugyo outbreak threaten disease control a…
The Times of India · Aug 22 Reactor blast at Telangana pharma unit kills 2, injures 9A reactor blast at a pharmaceutical unit in Telangana's Yadadri Bhuvanagiri district killed two workers and injured nine…
Google News · Aug 22 Exercise-mimicking weight-loss pill clears first human trialsEnveda's ENV-308, a novel obesity drug designed to replicate exercise's biochemical effects, has successfully completed …
Viés e Enquadramento
⚖
Science press release with neutral reporting of university research findings on CAR T-cell therapy improvements; minimal bias detected in straightforward presentation of preclinical study results.
Bias Direction
center
Confidence
HIGH
Standard academic press release framing emphasizing research innovation and institutional achievement. Uses expert authority and sequential discovery narrative to build credibility.
remarkably effective
promising new way
continued innovation
Limitations or skeptical views on CAR T-cell therapy scalability
Cost and accessibility concerns for patients
Perspectives from competing research groups or alternative treatment approaches
Patient experience or clinical trial participant voices
Timeline to human trials and realistic commercialization expectations
Impacto Geopolítico
🌎
This is a medical research article about CAR T-cell cancer therapy improvements, not a geopolitical matter.
Escalation Risk
N/A
Confidence
HIGH
Lente Econômica
📈
University of Maryland researchers identified cathepsin b protein blocking as a method to enhance CAR T-cell therapy effectiveness, potentially improving cancer treatment outcomes and reducing relapse rates in blood cancer patients.
Market Signal
bullish
Confidence
MED
Biotechnology and Pharmaceuticals
Healthcare and Medical Devices
Cancer Treatment and Oncology
Immunotherapy Development
Patients with recurrent or difficult-to-treat blood cancers could benefit from improved CAR T-cell therapy effectiveness, potentially reducing relapse rates (currently ~5 years) and improving survival outcomes. This could reduce long-term healthcare costs and improve quality of life for cancer patients.
FDA may accelerate review pathways for improved CAR T-cell therapies based on these findings. Potential increased funding for immunotherapy research through NIH and cancer research grants. Possible updates to clinical trial protocols for CAR T-cell therapies. Insurance coverage discussions may expand as efficacy improves.